Figure 6.

Impact of the mutation status and the generation of ADAs on serum chemokine serum concentrations in FD patients before and under ERT. (A–D) CCL2, (E–H) CCL17, (I–L) CXCL1, (M–P) CXCL8 and (Q–T) CXCL10 concentrations (pg/ml) in serum samples from FD patients with (A, E, I, M, Q) missense (n=9) or (B, F, J, N, R) nonsense (n=8) GLA mutations in (C, G, K, O, S) ADA-negative (n=6) or (D, H, L, P, T) ADA-positive (n=11) FD patients before (V0) or under ERT (V1). Red lines denote patients with missense mutations. Data were tested for normal distribution by Kolmogorov-Smirnov test. Differences between groups were determined by paired t-test (A–L, Q–T) or Wilcoxon matched-pairs signed rank test (M–P).